TY - JOUR
T1 - Extended-Release Naltrexone
T2 - A Qualitative Analysis of Barriers to Routine Use
AU - Alanis-Hirsch, Kelly
AU - Croff, Raina
AU - Ford, James H.
AU - Johnson, Kim
AU - Chalk, Mady
AU - Schmidt, Laura
AU - McCarty, Dennis
N1 - Funding Information:
Suzanne Gelber contributed to the conceptualization of the study and initial interviews; we thank her for her guidance. Amanda Abraham and Kim Hoffman reviewed and commented on the manuscript. An award from the National Institute on Drug Abuse (R01 DA029716) supported the Medication Research Partnership and the qualitative analysis. Dennis McCarty was the Principal Investigator on research service agreements with Alkermes and Purdue Pharma and he serves as a principal investigator and investigator on awards from the National Institutes of Health (UG1 DA015815, P50 DA018165, R01 DA030431, R01 MH1000001, and R33 DA035640). The other authors reported no conflicts.
Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - The Medication Research Partnership (a national health plan and nine addiction treatment centers contracted with the health plan) sought to facilitate the adoption of pharmacotherapy for alcohol and opioid use disorders. Qualitative analysis of interviews with treatment center change leaders, individuals working for the manufacturer and its technical assistance contractor, and health plan managers extracted details on the processes used to order, store, bill for, and administer extended-release naltrexone. Qualitative themes were categorized using domains from the Consolidated Framework for Implementation Research (intervention characteristics, outer setting, inner setting, and provider characteristics).Characteristics of XR-NTX that inhibited use included the complexity of ordering and using the medication; cost was also a barrier. Outer setting barriers reflected patient needs and external health plan policies on formulary coverage, benefit management, and reimbursement. Program structures, the lack of physician linkages, a culture resistant to the use of medication, and unease with change were inner setting elements that limited use of XR-NTX. Patient stereotypes and a lack of knowledge about XR-NTX affected practitioner willingness to treat patients and prescribe XR-NTX. The Consolidated Framework for Implementation Research provided a useful lens to understand and interpret the processes affecting access to XR-NTX.
AB - The Medication Research Partnership (a national health plan and nine addiction treatment centers contracted with the health plan) sought to facilitate the adoption of pharmacotherapy for alcohol and opioid use disorders. Qualitative analysis of interviews with treatment center change leaders, individuals working for the manufacturer and its technical assistance contractor, and health plan managers extracted details on the processes used to order, store, bill for, and administer extended-release naltrexone. Qualitative themes were categorized using domains from the Consolidated Framework for Implementation Research (intervention characteristics, outer setting, inner setting, and provider characteristics).Characteristics of XR-NTX that inhibited use included the complexity of ordering and using the medication; cost was also a barrier. Outer setting barriers reflected patient needs and external health plan policies on formulary coverage, benefit management, and reimbursement. Program structures, the lack of physician linkages, a culture resistant to the use of medication, and unease with change were inner setting elements that limited use of XR-NTX. Patient stereotypes and a lack of knowledge about XR-NTX affected practitioner willingness to treat patients and prescribe XR-NTX. The Consolidated Framework for Implementation Research provided a useful lens to understand and interpret the processes affecting access to XR-NTX.
KW - Barriers
KW - Consolidated framework for implementation research
KW - Extended-release naltrexone
KW - Naltrexone
UR - http://www.scopus.com/inward/record.url?scp=84955724908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955724908&partnerID=8YFLogxK
U2 - 10.1016/j.jsat.2015.10.003
DO - 10.1016/j.jsat.2015.10.003
M3 - Article
C2 - 26654934
AN - SCOPUS:84955724908
SN - 0740-5472
VL - 62
SP - 68
EP - 73
JO - Journal of Substance Abuse Treatment
JF - Journal of Substance Abuse Treatment
ER -